Man Who Predicted Bitcoin Says "This is Bigger"
He called Tesla in 2018... and Bitcoin in 2015... now he says a brand-new financial technology could unleash a Quadrillion-dollar impact starting 2021.
Learn More Here!

RPHM Insider Trading (Reneo Pharmaceuticals)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $17,881,825.77
Insider Selling (Last 12 Months): $0.00

Reneo Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Reneo Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Reneo Pharmaceuticals Share Price & Price History

Current Price: $8.64
Price Change: Price Increase of +0.53 (6.54%)
As of 09/24/2021 05:00 PM ET

This chart shows the closing price history over time for RPHM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The “Tech Royalty” Retirement Plan Can Help You Live Like Royalty
For the first time ever, a new type of tech investment allows you to collect ongoing income. One former Wall Street insider calls them, “Tech Royalties.”

And new “Tech Royalty” savings accounts allow you to collect as much as 8%... 12%... and even 17% or more.
Find out why “Tech Royalties” may be the best asse

Reneo Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2021Gregory J FlesherCEOBuy8,000$8.00$64,000.00View SEC Filing Icon  
8/25/2021Michael CruseVPBuy2,500$7.45$18,625.002,500View SEC Filing Icon  
8/25/2021Vineet R JindalCFOBuy5,000$7.44$37,200.005,000View SEC Filing Icon  
7/14/2021Bali MuralidharDirectorBuy111,736$8.50$949,756.00View SEC Filing Icon  
6/23/2021Bali MuralidharDirectorBuy20,710$9.28$192,188.80View SEC Filing Icon  
6/21/2021Bali MuralidharDirectorBuy32,659$9.03$294,910.77View SEC Filing Icon  
6/8/2021Bali MuralidharDirectorBuy16,605$9.50$157,747.50View SEC Filing Icon  
6/3/2021Bali MuralidharDirectorBuy12,100$9.25$111,925.00View SEC Filing Icon  
5/26/2021Bali MuralidharDirectorBuy5,915$9.38$55,482.70View SEC Filing Icon  
4/13/2021Holdings A/S NovoMajor ShareholderBuy666,666$15.00$9,999,990.002,763,711View SEC Filing Icon  
4/13/2021Niall O'donnellDirectorBuy200,000$15.00$3,000,000.00View SEC Filing Icon  
4/9/2021Venture Fund Iii L RivervestMajor ShareholderBuy200,000$15.00$3,000,000.00View SEC Filing Icon  
See Full Table
Insider Trading at Reneo Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Reneo Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Reneo Pharmaceuticals (NASDAQ:RPHM)

75.00% of Reneo Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RPHM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Reneo Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/23/2021Morgan Stanley31,190$0.29M0.0%N/A0.128%Search for SEC Filing on Google Icon
8/17/2021Caas Capital Management LP20,000$0.19M0.0%N/A0.082%Search for SEC Filing on Google Icon
8/16/2021California State Teachers Retirement System8,726$81K0.0%N/A0.036%Search for SEC Filing on Google Icon
8/16/2021RA Capital Management L.P.62,217$0.58M0.0%N/A0.255%Search for SEC Filing on Google Icon
8/16/2021Tudor Investment Corp Et Al13,406$0.13M0.0%N/A0.055%Search for SEC Filing on Google Icon
8/16/2021Morgan Stanley31,190$0.29M0.0%N/A0.128%Search for SEC Filing on Google Icon
8/16/2021Pinz Capital Management LP56,823$0.53M0.2%N/A0.233%Search for SEC Filing on Google Icon
8/16/2021Charles Schwab Investment Management Inc.13,371$0.13M0.0%N/A0.055%Search for SEC Filing on Google Icon
8/16/2021State Street Corp60,915$0.57M0.0%N/A0.250%Search for SEC Filing on Google Icon
8/16/2021Federated Hermes Inc.17,000$0.16M0.0%N/A0.070%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp68,447$0.64M0.0%N/A0.282%Search for SEC Filing on Google Icon
8/13/2021Franklin Resources Inc.500,000$4.67M0.0%N/A2.059%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC72,069$0.67M0.0%N/A0.297%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.366,210$3.42M0.0%N/A1.508%Search for SEC Filing on Google Icon
8/13/2021FMR LLC187,500$1.75M0.0%N/A0.772%Search for SEC Filing on Google Icon
8/12/2021JPMorgan Chase & Co.7,794$73K0.0%N/A0.032%Search for SEC Filing on Google Icon
8/11/2021RiverVest Venture Management LLC2,409,220$22.48M4.4%N/A9.920%Search for SEC Filing on Google Icon
8/11/2021Bank of New York Mellon Corp14,837$0.14M0.0%N/A0.061%Search for SEC Filing on Google Icon
8/11/2021BlackRock Inc.289,824$2.70M0.0%N/A1.193%Search for SEC Filing on Google Icon
8/11/2021Deutsche Bank AG3,745$35K0.0%N/A0.015%Search for SEC Filing on Google Icon
8/10/2021Nicholas Investment Partners LP226,189$2.11M0.1%N/A0.931%Search for SEC Filing on Google Icon
8/6/2021Aisling Capital Management LP886,075$8.27M1.3%N/A3.649%Search for SEC Filing on Google Icon
8/2/2021New York State Common Retirement Fund12,980$0.12M0.0%N/A0.053%Search for SEC Filing on Google Icon
8/2/2021NEA Management Company LLC4,786,921$44.66M0.6%N/A19.711%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Reneo Pharmaceuticals logo
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Read More on Reneo Pharmaceuticals

Today's Range

Now: $8.64
Low: $8.00
High: $8.99

50 Day Range

MA: $8.45
Low: $6.28
High: $11.07

52 Week Range

Now: $8.64
Low: $6.10
High: $17.18

Volume

71,972 shs

Average Volume

82,307 shs

Market Capitalization

$210.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Reneo Pharmaceuticals?

Reneo Pharmaceuticals' top insider shareholders include:
  1. Holdings A/S Novo (Major Shareholder)
  2. Vineet R Jindal (CFO)
  3. Michael Cruse (VP)
  4. Bali Muralidhar (Director)
  5. Gregory J Flesher (CEO)
  6. Niall O'donnell (Director)
  7. Venture Fund Iii L Rivervest (Major Shareholder)

Who are the major institutional investors of Reneo Pharmaceuticals?

Reneo Pharmaceuticals' top institutional investors include:
  1. NEA Management Company LLC — 19.71%
  2. RiverVest Venture Management LLC — 9.92%
  3. Aisling Capital Management LP — 3.65%
  4. Franklin Resources Inc. — 2.06%
  5. Vanguard Group Inc. — 1.51%
  6. BlackRock Inc. — 1.19%

Which major investors are buying Reneo Pharmaceuticals stock?

In the previous quarter, RPHM stock was acquired by institutional investors including:
  1. NEA Management Company LLC
  2. RiverVest Venture Management LLC
  3. Aisling Capital Management LP
  4. Franklin Resources Inc.
  5. Vanguard Group Inc.
  6. BlackRock Inc.
  7. Nicholas Investment Partners LP
  8. FMR LLC
During the last year, these company insiders have bought Reneo Pharmaceuticals stock:
  1. Holdings A/S Novo (Major Shareholder)
  2. Vineet R Jindal (CFO)
  3. Michael Cruse (VP)
  4. Bali Muralidhar (Director)
  5. Gregory J Flesher (CEO)
  6. Niall O'donnell (Director)
  7. Venture Fund Iii L Rivervest (Major Shareholder)
The “Tech Royalty” Retirement Plan Can Help You Live Like Royalty
For the first time ever, a new type of tech investment allows you to collect ongoing income. One former Wall Street insider calls them, “Tech Royalties.”

And new “Tech Royalty” savings accounts allow you to collect as much as 8%... 12%... and even 17% or more.
Find out why “Tech Royalties” may be the best asse